Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight management and diabetes, unlike the current EU-approved competitor from Novo Nordisk. Amgen and Novo Nordisk stocks also rose but lagged behind Lilly's gains. The next step is the European Commission's final decision, which will determine Foundayo's market entry and competitive position in Europe.
Eli Lilly's stock is up 4.18% on Pluang, trading at USD 1,292.22 with a market cap of $1.11T as of Oct 21, 2026 00:01 WIB. Amgen and Novo Nordisk also show gains, with Amgen up 2.27% and Novo Nordisk up 1.95% at the same time.
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achi...
Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipi...
